The U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab) for efficacy on July 31, 2017. This approval, submitted by Bristol Myers Squibb, signifies an update to the drug's approved uses based on new efficacy data.
Background
Nivolumab, marketed as Opdivo, is an established immunotherapy. As an immune checkpoint inhibitor, it works by blocking the PD-1 pathway, which can help the body's immune system recognize and fight cancer cells. This supplemental approval specifically addressed the efficacy profile of the drug, building upon its existing approvals.
What this means
A supplemental application approval for efficacy typically indicates that new clinical data supports an expanded or refined use for an already approved drug. While the specific details of the new indication, patient population, or dosing regimen are not provided in the source data, this approval confirms the FDA's acceptance of additional efficacy evidence for Opdivo (nivolumab). For clinicians, this means an updated label that may offer new treatment options or clarify existing ones for patients, potentially broadening the scope of its application in clinical practice.
Source
This information was sourced from the U.S. Food and Drug Administration (FDA) on July 31, 2017. The details are available on the FDA's website, accessdata.fda.gov, under the supplemental application BLA 125554 S-34.